Pharmaceuticals News and Research

RSS

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

miRagen Therapeutics, Inc., a privately-held biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's compound MGN-4893 for the treatment of polycythemia vera, a myeloproliferative disease characterized by an overabundance of blood cells and platelets in the body.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Iris Pharma announces validation of new EIU model of ocular inflammation

Iris Pharma, a world leader CRO specialized in ophthalmology, today announced the validation of the Endotoxin-Induced Uveitis model, a new model of ocular inflammation.

17 Feb 2011

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Progenics Pharmaceuticals, Inc. today reported positive preliminary data from an ongoing phase 1 study of PSMA ADC, an antibody-drug conjugate designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen.

17 Feb 2011

Inspire announces strategic corporate restructuring on its eye care business

Inspire Pharmaceuticals, announced today a strategic corporate restructuring designed to result in the Company focusing activities on its eye care business, allowing it to fully leverage existing commercial capabilities, pipeline assets and related corporate development and licensing opportunities.

17 Feb 2011

Inspire fourth quarter revenues increase 2% to $30.3 million

Inspire Pharmaceuticals, announced today financial results for the fourth quarter and year ended December 31, 2010. For the quarter ended December 31, 2010, the Company reported a net loss of $4.3 million, or per common share, compared to a net loss of $2.6 million, or per common share, for the same period in 2009.

17 Feb 2011

Researchers discover substance that reinforces brain's self-healing functions after stroke

The only acute treatment for a stroke currently available is thrombolysis. This uses drugs that dissolve the blood clot responsible for the stroke, but it only reaches around 10 per cent of stroke patients in time to prevent lasting damage. For other patients, there are no other effective drugs that reduce the loss of brain function following a stroke.

17 Feb 2011

ICR, AB SCIEX collaborate to standardize mass spectrometry-based tissue imaging

A key research area for The Institute of Cancer Research is investigating the spread of cancer in the human body in an effort to identify new and effective treatment strategies. To help advance this research, the ICR is collaborating with scientists at AB SCIEX, a global leader in life science analytical technologies, to standardize advanced methods of mass spectrometry-based tissue imaging.

17 Feb 2011

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders. The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e., neurturin or NRTN, intended to restore and preserve dying neurons.

17 Feb 2011

ASN opposes proposed $1.6 billion reduction to NIH budget

Proposed cuts to the National Institutes of Health (NIH) budget for 2011 will limit the nation's ability to advance patient care and public health.

17 Feb 2011

Poll: 73% of New Jersey people think investment on global health research is important to state's economy

Despite the unpredictable economy, nearly three-quarters of New Jersey residents think spending money on research to improve health globally is important to jobs and incomes in the state, according to a new statewide poll commissioned by Research!America.

17 Feb 2011

Medicaid should stop paying more than Medicare for pharmacy benefits

To help reduce state Medicaid spending, the New York State Health Department yesterday proposed that the program's prescription drug benefits be managed more like those in Medicare and commercial plans. The Department's "Proposal to Redesign Medicaid" says this move would save state taxpayers $350 million though 2015.

17 Feb 2011

EMA publishes concept paper on pharmaceutical cold storage conditions during transport

The European Medicines Agency has published a concept paper on storage conditions during transport. The goal is to create new Good Distribution Practice and GMP guidance and may lead to the need to revise the guideline on declaration of storage conditions.

From IQPC Ltd 17 Feb 2011

States grapple with new ways to cut state Medicaid costs

Among the strategies being used are efforts to change rules, revise definitions, tighten anti-fraud efforts and cut services.

17 Feb 2011

FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma

Threshold Pharmaceuticals, Inc. today announced that the Company reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a Phase 3 randomized trial of TH-302 in patients with soft tissue sarcoma.

17 Feb 2011

ACEA Biosciences receives new U. S. Patent for chemical compound screening

ACEA Biosciences, a pioneer in the development of high-performance microelectronic systems for cell-based assays, diagnostics, and pharmaceutical research, is pleased to report the issuance of a new U. S. Patent for chemical compound screening, with important applications in the development of new pharmaceutical products.

17 Feb 2011

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

17 Feb 2011

BD announces addition of new flow cytometry system for rapid microbial enumeration, detection

Industrial microbiologists now have a new tool that was designed specifically to help quality control laboratories rapidly screen raw materials, as well as in-process and finished goods, for the presence of microorganisms that can threaten product quality.

17 Feb 2011

New fully human monoclonal antibodies to battle Chikungunya

The Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and VIVALIS, a French biopharmaceutical company, announced today the discovery of two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment.

16 Feb 2011

Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial

Endo Pharmaceuticals and Bioniche Life Sciences Inc., today announced enrollment of the first patient in the second Phase III clinical trial of Urocidin.

16 Feb 2011

Pharmaceuticals News and Research

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Iris Pharma announces validation of new EIU model of ocular inflammation

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Inspire announces strategic corporate restructuring on its eye care business

Inspire fourth quarter revenues increase 2% to $30.3 million

Researchers discover substance that reinforces brain's self-healing functions after stroke

ICR, AB SCIEX collaborate to standardize mass spectrometry-based tissue imaging

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

ASN opposes proposed $1.6 billion reduction to NIH budget

Poll: 73% of New Jersey people think investment on global health research is important to state's economy

Medicaid should stop paying more than Medicare for pharmacy benefits

EMA publishes concept paper on pharmaceutical cold storage conditions during transport

States grapple with new ways to cut state Medicaid costs

FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma

ACEA Biosciences receives new U. S. Patent for chemical compound screening

Astellas, AVEO enter development, commercialization agreement for tivozanib

BD announces addition of new flow cytometry system for rapid microbial enumeration, detection

New fully human monoclonal antibodies to battle Chikungunya

Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence